Table 3. Final model pharmacokinetic parameters.
| Final Pharmacokinetic Model | Parameter | SE(%CV) |
| Ka (hr−1) | 0.300 Fixed | N/A |
| V (L) | 94.5 | 24.4% |
| CL (L/hr) – CYP2B6*6 (*6/*6) – Homozygous Mutant | 4.54 | 11.9% |
| CL (L/hr) – CYP2B6*6 (*1/*6) – Heterozygous Mutant | 7.92 | 33.5% |
| CL (L/hr) – CYP2B6*6 (*1/*1) – Wild-Type | 9.99 | 26.8% |
| F1 - ABRS 1&2 | 1 Fixed | N/A |
| F1 - ABRS 3 | 0.780 | 40.7% |
| F1 - ABRS 4 | 0.513 | 30.4% |
| IIV CL | 0.134 | 19.9% |
| RV – Proportional (%CV) | 17.3 | 26.3% |
| RV – Additive (ng/mL) | 348 | 31.3% |
Ka = Mean population absorption rate constant, V = Mean population Volume of distribution, CL = Mean population clearance, F1 = Bioavailability fraction, IIV CL = inter-individual variability on Clearance in the population, RV = residual variability.